39 results on '"Conroy T"'
Search Results
2. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
3. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
4. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
5. Moving toward precision oncology centers V2.0
6. 1215P Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
7. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
8. Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in regard to "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up") by Huguet et al
9. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial
10. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
11. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
12. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
13. LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
14. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
15. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab†
16. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel†
17. 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs)
18. LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
19. Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
20. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
21. 1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial
22. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors
23. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients
24. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
25. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study
26. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
27. Standards, options and recommendations for the clinical care of colon cancer.
28. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45
29. Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
30. COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT)
31. LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
32. 193O - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45
33. 477O - Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
34. 746P - COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT)
35. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial
36. Impact of Response Shift On Time to Quality of Life Scores Deterioration in Breast Cancer Patients: Is it Time to Move For QOL Recist Criterion?
37. Item Response Theory and Factor Analysis as Mean to Characterize Occurrence of Response Shift for Longitudinal Quality of Life Study in Breast Cancer Patients
38. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: A French cooperative study
39. LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.